AMAG Pharmaceuticals (AMAG Pharmaceuticals) Days Payable : 77.59 (As of Sep. 2020)

View and export this data going back to 1986. Start your Free Trial

What is AMAG Pharmaceuticals Days Payable?

AMAG Pharmaceuticals's average Accounts Payable for the three months ended in Sep. 2020 was $11.3 Mil. AMAG Pharmaceuticals's Cost of Goods Sold for the three months ended in Sep. 2020 was $13.3 Mil. Hence, AMAG Pharmaceuticals's Days Payable for the three months ended in Sep. 2020 was 77.59.

The historical rank and industry rank for AMAG Pharmaceuticals's Days Payable or its related term are showing as below:

AMAG's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 148.78
* Ranked among companies with meaningful Days Payable only.

AMAG Pharmaceuticals's Days Payable declined from Sep. 2019 (115.66) to Sep. 2020 (77.59). It may suggest that AMAG Pharmaceuticals accelerated paying its suppliers.

AMAG Pharmaceuticals Days Payable Historical Data

The historical data trend for AMAG Pharmaceuticals's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AMAG Pharmaceuticals Days Payable Chart

AMAG Pharmaceuticals Annual Data

Trend

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Days Payable

Get a 7-Day Free Trial

25.17

16.28

12.90

18.77

70.67

AMAG Pharmaceuticals Quarterly Data
	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20
Days Payable	Get a 7-Day Free Trial															115.66	56.42	81.55	73.94	77.59

Competitive Comparison of AMAG Pharmaceuticals's Days Payable

For the Biotechnology subindustry, AMAG Pharmaceuticals's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AMAG Pharmaceuticals's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AMAG Pharmaceuticals's Days Payable distribution charts can be found below:

* The bar in red indicates where AMAG Pharmaceuticals's Days Payable falls into.

AMAG Pharmaceuticals Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

AMAG Pharmaceuticals's Days Payable for the fiscal year that ended in Dec. 2019 is calculated as

	Days Payable (A: Dec. 2019 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2018 )	+	Accounts Payable (A: Dec. 2019 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2019 )	*	Days in Period
=	( (14.487	+	27.021)	/	2 )	/	107.193	*	365
=	20.754					/	107.193	*	365
=	70.67

AMAG Pharmaceuticals's Days Payable for the quarter that ended in Sep. 2020 is calculated as:

	Days Payable (Q: Sep. 2020 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2020 )	+	Accounts Payable (Q: Sep. 2020 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2020 )	*	Days in Period
=	( (12.944	+	9.742)	/	2 )	/	13.34	*	365 / 4
=	11.343					/	13.34	*	365 / 4
=	77.59

AMAG Pharmaceuticals Days Payable Related Terms

Thank you for viewing the detailed overview of AMAG Pharmaceuticals's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

AMAG Pharmaceuticals (AMAG Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AMAG Pharmaceuticals Inc (NAS:AMAG) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

1100 Winter Street, Waltham, MA, USA, 02451

Website

https://www.amagpharma.com

AMAG Pharmaceuticals Inc primarily uses its nanoparticle technology to develop therapeutic compounds to treat anemia in patients suffering from chronic kidney disease, as well as imaging agents that assist in identifying cancerous tumors. The company recently received Food and Drug Administration approval for Feraheme, a novel iron replacement drug for CKD patients suffering from anemia, and also offers GastroMARK, an imaging aid used with magnetic resonance imaging. Most of the revenues are generated through the sale of Feraheme and Makena which is a hydroxyprogesterone caproate injection.

Executives

Camber Capital Management Lp	10 percent owner	101 HUNTINGTON AVENUE, SUITE 2101, BOSTON MA 02199
Anthony Casciano	officer: Chief Operating Officer	C/O AMAG PHARMACEUTICALS, INC. 1100 WINTER STREET WALTHAM MA 02451
Brian Piekos	officer: Interim CFO	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
David Edward Johnson	director, 10 percent owner	590 MADISON AVENUE, NEW YORK NY 10022
James R Sulat	director
Davey Scoon	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
John A. Fallon	director	C/O INSULET CORPORATION, 9 OAK PARK DRIVE, BEDFORD MA 01730
Anne M. Phillips	director	C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Paul R. Fonteyne	director	C/O RESTORBIO, INC., 501 BOYLSTON STREET SUITE 6102, BOSTON MA 02116
Gino Santini	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Scott Dunseth Myers	director, officer: President & CEO	C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Kelly Schick	officer: Chief Human Resources Officer	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Armistice Capital, Llc	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Armistice Capital Master Fund Ltd.	10 percent owner	C/O ARMISTICE CAPITAL, LLC, 510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022
Steven Boyd	10 percent owner	510 MADISON AVENUE, 7TH FLOOR, NEW YORK NY 10022